GHK-Cu

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

GHK-Cu is a small copper-binding tripeptide — the three amino acids glycine, histidine, and lysine, complexed with a copper(II) ion — that occurs naturally in human plasma. Plasma levels start at roughly 200 ng/mL in your twenties and decline by sixty percent or more by your sixties. The molecule has been characterized in peer-reviewed dermatology and biochemistry literature since the 1970s, primarily by Loren Pickart's group, making it one of the longest-studied cosmetic peptides in commercial use.

What makes GHK-Cu interesting clinically is the breadth of its biological activity. Whole-genome studies show that exposure to the peptide modulates over four thousand human genes — switching off pathways associated with tissue breakdown, switching on pathways associated with collagen synthesis, antioxidant defense, and wound repair. That gene-level breadth explains why it shows up across cosmetic, wound-healing, hair-density, and post-procedure recovery contexts.

In the United States, topical GHK-Cu is regulated as a cosmetic, not a drug. Injectable GHK-Cu was placed on the FDA's interim Category 2 list in 2023, which means compounding pharmacies cannot legally dispense it for systemic use. The topical regulatory status is unaffected.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

The "Cu" in the name is doing real work. Copper is an essential cofactor for several enzymes involved in connective-tissue maintenance — most importantly lysyl oxidase, which cross-links new collagen and elastin fibers into stable, mature matrix. GHK-Cu acts as a chaperone that delivers copper to these enzymes, raising local effective copper without the safety concerns of free ionic copper.

Beyond the copper-delivery role, the GHK tripeptide itself binds to specific transcription factors and changes gene expression. The well-replicated effects:

• Suppression of matrix metalloproteinases (MMPs), the enzymes that degrade collagen during photoaging and inflammation.
• Upregulation of type I and type III collagen synthesis.
• Increased glycosaminoglycan production in the dermis.
• Induction of antioxidant enzymes like superoxide dismutase and catalase.
• Anti-inflammatory effects via NF-κB modulation.

In wound-healing models the net effect is faster closure with less scarring. In skin-aging models the net effect is measurable improvements in dermal thickness, elasticity, and wrinkle depth over twelve weeks of consistent topical use.

What the evidence actually shows

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

GHK-Cu's evidence base is broader than most cosmetic actives but narrower than retinoids or sunscreens. The practical reality:

• Topical cosmetic effects. Multiple small RCTs (n=30 to 80 typical) over twelve to twenty-four weeks consistently show measurable improvements in skin thickness, elasticity, and wrinkle depth. Effect sizes are smaller than tretinoin but with no irritation tradeoff. The evidence base here is genuinely useful.
• Wound healing. Strong animal model evidence; smaller human studies show accelerated closure of chronic ulcers and post-surgical wounds. Used clinically in some hospital protocols outside the US.
• Hair density. Mixed evidence. Some small trials show benefit; others do not. Mechanism is plausible but effect sizes are inconsistent.
• Systemic anti-aging. Hypotheses based on the gene-modulation breadth; not directly demonstrated in human outcome trials.

The gap to watch: most "GHK-Cu reverses skin aging" claims rest on the dermal-thickness studies, which are genuine but modest in effect size. Anyone reading marketing copy that suggests dramatic skin transformation should adjust their expectations downward by about half.

Reported benefits

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Across the cosmetic and dermatology literature plus aggregated user reports:

• Improved skin elasticity, fine line depth, and overall texture over 8–12+ weeks topical use.
• Faster recovery after CO2 laser, microneedling, chemical peels, and post-surgical wound healing.
• Reduced redness and irritation in reactive or post-procedure skin.
• Modest hair density improvements (effect not consistent).
• Anti-inflammatory benefit in eczema-prone or sensitized skin.
• Theoretical and small-trial wound-healing benefits when used as part of a clinical regimen.

In a head-to-head comparison with retinol for general anti-aging purposes, GHK-Cu typically loses on raw effect size but wins on tolerability — making it the better first-line topical for damaged or reactive skin.

Risks and reported side effects

Evidence tier: 3 — clinical case-series + animal-model adverse-event data; magnitude varies by molecule.

Topical GHK-Cu is one of the best-tolerated active cosmetic ingredients. Side effects across published trials and aggregate user reports are mild and uncommon:

• Mild stinging or warmth on application — usually formulation-related, resolves with vehicle change.
• Rare allergic contact dermatitis — like any topical, possible but uncommon.
• Theoretical greenish or coppery skin discoloration at very high concentrations — formulation-specific, rarely reported in cosmetic-grade products.
• No systemic side effects documented at cosmetic doses.

Important caveats:

• Wilson's disease and other copper-metabolism disorders — even topical copper exposure should be discussed with a clinician. Documented adverse events are theoretical rather than reported, but the mechanism is non-zero.
• Active eczema or compromised skin barrier — GHK-Cu is generally barrier-supportive, but any product with a non-trivial preservative system can sting on broken skin. Patch test first.
• Interaction with high-concentration vitamin C or strong retinoids — copper can theoretically catalyze oxidation of these molecules, reducing potency of both. Apply at separate times of day to be safe.

For the injectable form (Category 2 in the US): substantially less safety data than topical, no consistent dosing protocols, and a real risk of contamination from non-pharmaceutical sources. The cost-benefit shifts unfavorably outside of a clinical research setting.

Practical considerations

Evidence tier: 5 — community-evolved dose-range guidance; not RCT-derived.

If you are using or considering GHK-Cu topically:

• Concentration. Cosmetic-grade serums typically range from 0.05% to 3%. Higher is not always better — penetration plateaus and cost climbs.
• Vehicle. Penetration depends heavily on the carrier. Water-based serums penetrate more than heavy creams. Liposome-encapsulated formulations claim better delivery but add cost.
• pH. Below 5, the peptide degrades quickly. Look for products with a stated pH of 5.5–7. If the label doesn't disclose, the product probably doesn't pass that bar.
• Packaging. Light and air degrade the active. Opaque, airless pump packaging is a real feature. Clear-jar or screw-top products are usually significantly degraded by purchase.
• Routine placement. Most users apply twice daily, alone or layered before moisturizer. If using with retinoids, alternate days or AM/PM separation is the safest approach.
• Time to result. Skin texture and softness changes are commonly reported within 2–4 weeks. The published improvements in wrinkle depth and elasticity appear over 8–12 weeks of consistent use.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For the head-to-head comparison with retinol on barrier-repair indications, see our supporting article on GHK-Cu vs Retinol. For the broader Skin & Anti-Aging pillar, see the goal-based hub. For an alternative copper peptide application — hair density — that surface is on the Phase 1 roadmap.

If you are a dermatology clinician interested in becoming a Medical Reviewer for our Skin & Anti-Aging cluster content, see the Medical Review Process page.

Related on Peptide Story

• Skin & Anti-Aging pillar — copper-peptide context
• GHK-Cu vs Tretinoin — head-to-head
• GHK-Cu vs retinol barrier comparison

References

• Pickart L., Margolina A. 2018. Regenerative and protective actions of the GHK-Cu peptide in the light of new gene-data.
• Pickart L. 2015. The human tripeptide GHK and tissue remodeling. BioMed Res Int.